118 related articles for article (PubMed ID: 10865983)
1. Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Döhner K; Schlenk RF; van der Reijden BA; Döhner H
Leukemia; 2000 Jun; 14(6):1154. PubMed ID: 10865983
[No Abstract] [Full Text] [Related]
2. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.
van Der Kolk DM; Vellenga E; van Der Veen AY; Noordhoek L; Timmer-Bosscha H; Ossenkoppele GJ; Raymakers RA; Müller M; van Den Berg E; de Vries EG
Blood; 2000 Jun; 95(11):3514-9. PubMed ID: 10828037
[TBL] [Abstract][Full Text] [Related]
3. [The current chemotherapy of acute myeloid leukemias in adults].
Poddubnaia IV; Perilov AA
Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791
[No Abstract] [Full Text] [Related]
4. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
5. New agents in the treatment of acute myeloid leukemia.
Wiernik PH
Semin Hematol; 1991 Jul; 28(3 Suppl 4):95-8. PubMed ID: 1780763
[No Abstract] [Full Text] [Related]
6. Role of MRP1 in multidrug resistance in acute myeloid leukemia.
Legrand O; Zittoun R; Marie JP
Leukemia; 1999 Apr; 13(4):578-84. PubMed ID: 10214864
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
McHayleh W; Sehgal R; Redner RL; Raptis A; Agha M; Natale J; Luong TM; Schlesselman JJ; Foon KA; Boyiadzis M
Leuk Lymphoma; 2009 Nov; 50(11):1848-53. PubMed ID: 19860628
[TBL] [Abstract][Full Text] [Related]
8. [Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Zhou HF; Li JY; Qian SX; Qiu HR; Zhang SJ; Zhang JF; Wu YJ; Shen RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):1033-7. PubMed ID: 17096914
[TBL] [Abstract][Full Text] [Related]
9. Deletion of the multidrug resistance protein 1 (MRP1) gene in acute myeloid leukemia patients with inversion 16: expression of MRP1 homologues.
van der Kolk DM; de Vries EG; Vellenga E
Leukemia; 2001 Jan; 15(1):191-2. PubMed ID: 11243393
[No Abstract] [Full Text] [Related]
10. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
12. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
13. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
14. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Seiter K; Feldman EJ; Sreekantaiah C; Pozzuoli M; Weisberger J; Liu D; Papageorgio C; Weiss M; Kancherla R; Ahmed T
Leukemia; 2001 Jun; 15(6):963-70. PubMed ID: 11417484
[TBL] [Abstract][Full Text] [Related]
15. Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene.
Krumbholz M; Jung R; Bradtke J; Reinhardt D; Stachel D; Metzler M
Leuk Lymphoma; 2015 Mar; 56(3):793-6. PubMed ID: 24884312
[No Abstract] [Full Text] [Related]
16. Treatment of relapsed and refractory acute myeloid leukemia in adults.
Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
[No Abstract] [Full Text] [Related]
17. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
18. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular remission in a case of acute myeloid leukaemia(AML) with inversion of chromosome 16 (Inv(16)) and Philadelphia chromosome (Ph).
Preudhomme C; Lai JL; Plantier I; Demory JL; Zandecki M; Fenaux P
Br J Haematol; 1992 Nov; 82(3):623-6. PubMed ID: 1486046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
